Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]
Alumis Inc. (ALMS)
Company Research
Source: Yahoo! Finance
16 and roughly ~40% PASI100 at week 24 — with rapid onset and marked itch and DLQI improvements. Safety/tolerability through 24 weeks was favorable, with the most common adverse event being headache (~10%), no major lab abnormalities reported, low serious infections and malignancies, and no TB reactivation observed among patients with latent TB. Alumis plans to pursue an NDA filing, expects a pivotal-designed Phase IIb lupus readout in Q3, is collecting longer-term extension data, and views partnering as likely for global commercialization. Interested in Alumis Inc.? Here are five stocks we like better. 3 Biopharmaceutical Stocks Bucking the Sell-Off Alumis (NASDAQ:ALMS) used a virtual key opinion leader event from the American Academy of Dermatology (AAD) Congress to spotlight phase III results for envudeucitinib (also referred to as ESK-001), its next-generation oral TYK2 inhibitor being developed for moderate-to-severe plaque psoriasis. The webcast featured remarks from C
Show less
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]Yahoo! Finance
- Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
- Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.MarketBeat
- Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis [Yahoo! Finance]Yahoo! Finance
ALMS
Sec Filings
- 4/7/26 - Form SCHEDULE
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- ALMS's page on the SEC website